Enovis reports third-quarter net sales of $549 million and net loss of $571 million

Enovis Corporation reported third-quarter 2025 net sales of $549 million, representing a 9.0% increase on a reported basis and 7.0% growth organically compared to the same period in 2024. Reconstructive sales grew 12.0% on a reported basis and 9.0% organically, while Prevention & Recovery sales increased 6.0% on a reported basis and 4.0% organically. The company reported a third-quarter net loss of $571 million, primarily due to a $548 million non-cash goodwill impairment charge, resulting in a net loss of $9.99 per share. Adjusted EBITDA for the quarter was $95 million, or 17.3% of sales, and adjusted net earnings per diluted share were $0.75. For full-year 2025, Enovis updated its financial outlook, expecting revenue in the range of $2.24 to $2.27 billion, reflecting a $15 million reduction following the divestiture of its Diabetic Footcare business unit in October 2025. Adjusted EBITDA is forecasted at $395-405 million, and adjusted earnings per share guidance was raised to $3.10-3.25. The divestiture is expected to generate up to $60 million in proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enovis Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570082-en) on November 06, 2025, and is solely responsible for the information contained therein.